Biotech entity
Every one of those 1 sits in a single category, clinical-trial. Center for Biologics Evaluation and Research is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Dr. Craig Eagle appears in 1 tracked Biotech story from August 14, 2026.
Last mentioned: Aug 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Center for Biologics Evaluation and Research is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Dr. Craig Eagle appears in 1 tracked Biotech story from August 14, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Craig Eagle. Shared-story counts are live from our verified record — not editorial picks.
Interim 3-year overall survival data expected
Company expects to announce interim 3-year overall survival data from the Phase 2b OST-HER2 trial in early September 2026.
FDA Type C Statistical Methods Meeting
Meeting expected in mid-September 2026 with CBER to review statistical methods, comparator appropriateness, RMAT designation, and rolling review.
MHRA Scientific Advice Meeting
UK MHRA meeting expected in September 2026 to review statistical methods supporting the CMAA, including finalization with 2.5-year overall survival.
Company announces FDA Type C meeting and MHRA parallel review
OS Therapies announces FDA granted Type C Statistical Methods Meeting to review 2.5-year OS data for OST-HER2; MHRA Scientific Advice Meeting granted in parallel.
Biotech stakeholders are watching OST-HER2's FDA Type C meeting because the statistical comparator decision could de-risk or delay a rare oncology asset. With 3-year survival data due days earlier and MHRA engagement in parallel, the event sequence is a near-term catalyst.
Source: The Kingston Whig Standard · Financialcontent
Dr. Craig Eagle is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
